Daniel O’Day’s I/O dance con­tin­ues, as Gilead and Tan­go ex­pand deal up to $6B

Three years ago, Gilead CEO John Mil­li­gan signed a mile­stone-heavy deal with a lit­tle-known biotech that had flashy tech­nol­o­gy and flashier founders. Now, with new chief Daniel O’Day on a can­cer ther­a­py shop­ping spree, the two com­pa­nies are up­grad­ing that deal in­to a po­ten­tial be­he­moth.

Gilead and Boston’s Tan­go Ther­a­peu­tics agreed to an up to $6 bil­lion deal that will cov­er 15 dif­fer­ent tar­gets that help can­cer cells evade the im­mune sys­tem, paving the way for drugs that could be used in com­bi­na­tion with check­point in­hibitors for the rest of their grow­ing im­muno-on­col­o­gy port­fo­lio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER